Company profile
Exicure, Inc.
NASDAQ: XCUR · Healthcare · Biotechnology
#1163 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
31DFH 31DQ 32GM 33SS 28
v0.1 · 65/100 weight · provisional
↑ growth stability, return on assets · ↓ workforce scale, revenue growth (YoY)
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$4.9M
Employees
1
as of 2026-09-20
Market cap
$7.8M
as of 2026-09-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$4.9M-$4.9M2025
Operating income-$4.2M-$4.2M2025
Total assets$14.0M$14.0M2025
Liabilities$10.1M$10.1M2025
Equity$3.9M$3.9M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Exicure, Inc.’s revenue?
Exicure, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
PreveCeutical Medical Inc.——Integrated Cannabis Solutions, Inc.——ENDRA Life Sciences Inc.25DVynleads, Inc.20DRevive Therapeutics Ltd.——Sweet Earth Holdings Corporation——Neighbors
Cook →Key facts
CEOJungsoo Kim
SectorHealthcare
IndustryBiotechnology
HeadquartersChicago, IL
ExchangeNASDAQ: XCUR
Employees1
IPO date2018-05-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.